ES2195366T3 - Modificacion termodinamicamente estable de 1-(4-carbazoliloxi)-4-(2-(2-metoxifenoxi)etillamino)-2-propanol, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen. - Google Patents

Modificacion termodinamicamente estable de 1-(4-carbazoliloxi)-4-(2-(2-metoxifenoxi)etillamino)-2-propanol, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.

Info

Publication number
ES2195366T3
ES2195366T3 ES98937576T ES98937576T ES2195366T3 ES 2195366 T3 ES2195366 T3 ES 2195366T3 ES 98937576 T ES98937576 T ES 98937576T ES 98937576 T ES98937576 T ES 98937576T ES 2195366 T3 ES2195366 T3 ES 2195366T3
Authority
ES
Spain
Prior art keywords
propanol
thermodynamically stable
preparation
metoxifenoxi
etillamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98937576T
Other languages
English (en)
Inventor
Erhard Reinholz
Peter Beyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Application granted granted Critical
Publication of ES2195366T3 publication Critical patent/ES2195366T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a nuevas modificaciones termodinámicamente estables de 1-(4-carbazoliloxi)-3-[2-(2-metoxifenoxi)etilamino]-2-propanol (Carvedilol), las sales farmacológicamente aceptables, o las formas ópticamente activas de éste, procedimientos para la preparación, y compuestos farmacéuticos que los contienen.
ES98937576T 1997-07-22 1998-07-18 Modificacion termodinamicamente estable de 1-(4-carbazoliloxi)-4-(2-(2-metoxifenoxi)etillamino)-2-propanol, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen. Expired - Lifetime ES2195366T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97112491A EP0893440A1 (en) 1997-07-22 1997-07-22 Thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containing it

Publications (1)

Publication Number Publication Date
ES2195366T3 true ES2195366T3 (es) 2003-12-01

Family

ID=8227094

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98937576T Expired - Lifetime ES2195366T3 (es) 1997-07-22 1998-07-18 Modificacion termodinamicamente estable de 1-(4-carbazoliloxi)-4-(2-(2-metoxifenoxi)etillamino)-2-propanol, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.

Country Status (31)

Country Link
EP (2) EP0893440A1 (es)
JP (1) JP2001510824A (es)
KR (1) KR100336229B1 (es)
CN (1) CN1125047C (es)
AR (1) AR015133A1 (es)
AT (1) ATE236123T1 (es)
AU (1) AU740453B2 (es)
BR (1) BR9810776A (es)
CA (1) CA2296637C (es)
CZ (1) CZ296947B6 (es)
DE (1) DE69812964T2 (es)
DK (1) DK1000027T3 (es)
ES (1) ES2195366T3 (es)
HR (1) HRP980406A2 (es)
HU (1) HUP0003198A3 (es)
IL (1) IL133677A (es)
MA (1) MA26523A1 (es)
MY (1) MY117734A (es)
NO (1) NO313588B1 (es)
NZ (1) NZ502136A (es)
PE (1) PE96999A1 (es)
PL (1) PL191602B1 (es)
PT (1) PT1000027E (es)
RU (1) RU2202542C2 (es)
SI (1) SI1000027T1 (es)
TR (1) TR200000148T2 (es)
TW (1) TW505631B (es)
UY (1) UY25108A1 (es)
WO (1) WO1999005105A1 (es)
YU (1) YU2200A (es)
ZA (1) ZA986475B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003528914A (ja) * 2000-04-03 2003-09-30 エフ．ホフマン−ラ ロシュ アーゲー カルベジロールの濃縮溶液
EP1655285A1 (en) * 2000-06-28 2006-05-10 Teva Pharmaceutical Industries Ltd. Method for preparation of a crystalline form of carvedilol (form II)
JP2004501191A (ja) 2000-06-28 2004-01-15 テバ　ファーマシューティカル　インダストリーズ　リミティド カルベジロール
AU2002326391A1 (en) * 2001-07-13 2003-01-29 Smithkline Beecham Corporation Carvedilol polymorph
ATE381924T1 (de) 2001-09-21 2008-01-15 Egalet As Feste dispersionen mit kontrollierter freisetzung von carvedilol
WO2003029214A1 (en) * 2001-09-28 2003-04-10 F. Hoffmann-La Roche Ag Pseudopolymorphic forms of carvedilol
KR20040077872A (ko) 2002-01-15 2004-09-07 테바 파마슈티컬 인더스트리즈 리미티드 카베디롤의 결정질 고체 및 그 제조 방법
AU2003231283A1 (en) * 2002-04-30 2003-11-17 Sb Pharmco Puerto Rico Inc. Carvedilol monocitrate monohydrate
JP2005533822A (ja) 2002-06-27 2005-11-10 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド 臭化水素酸カルベジロール
KR101468827B1 (ko) 2002-06-27 2014-12-03 스미스클라인 비이참 (코르크) 리미티드 카베딜롤 인산염 및(또는) 그의 용매화물, 상응하는 조성물, 및(또는) 치료 방법
AU2003275953A1 (en) * 2002-11-08 2004-06-07 Egalet A/S Controlled release carvedilol compositions
WO2004084868A1 (en) 2003-03-26 2004-10-07 Egalet A/S Morphine controlled release system
EP1615888A1 (en) * 2003-04-21 2006-01-18 Matrix Laboratories Ltd Process for the preparation of carvedilol form-ii
SI21616A (sl) * 2003-09-02 2005-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Nove kristalne oblike karvedilola
EP1686986A4 (en) * 2003-11-25 2009-05-27 Sb Pharmco Inc CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF ADMINISTRATION AND / OR TREATMENT
PT1838670E (pt) * 2004-12-09 2009-12-18 Zach System Spa Processo para a preparação de carvedilol e seus enantiómeros
EP1781611A1 (en) * 2005-06-09 2007-05-09 Teva Pharmaceutical Industries Ltd. Crystalline forms of carvedilol and processes for their preparation
WO2008002683A2 (en) 2006-06-28 2008-01-03 Teva Pharmaceutical Industries Ltd. Polymorphous forms of carvedilol phosphate
RU2366653C2 (ru) * 2006-07-03 2009-09-10 Ооо "Нанокриохимия" Способ получения рентгеноаморфной модификации карведилола
US20080249317A1 (en) * 2007-04-04 2008-10-09 Apotex Inc. Novel amorphous form of carvedilol phosphate and processes for the preparation thereof
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE2805404A1 (de) * 1978-02-09 1979-08-16 Merck Patent Gmbh 1-aryloxy-3-nitratoalkylamino-2-propanole und verfahren zu ihrer herstellung
DE3319027A1 (de) * 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten

Also Published As

Publication number Publication date
EP0893440A1 (en) 1999-01-27
IL133677A (en) 2004-06-01
CZ2000221A3 (cs) 2000-05-17
NO20000301L (no) 2000-01-21
TW505631B (en) 2002-10-11
HUP0003198A2 (en) 2001-03-28
CA2296637A1 (en) 1999-02-04
KR20010022097A (ko) 2001-03-15
BR9810776A (pt) 2000-09-19
NO20000301D0 (no) 2000-01-21
HRP980406A2 (en) 1999-04-30
AU740453B2 (en) 2001-11-01
DE69812964D1 (de) 2003-05-08
IL133677A0 (en) 2001-04-30
WO1999005105A1 (en) 1999-02-04
NZ502136A (en) 2002-05-31
EP1000027B1 (en) 2003-04-02
PE96999A1 (es) 1999-10-12
MA26523A1 (fr) 2004-12-20
DE69812964T2 (de) 2004-03-04
NO313588B1 (no) 2002-10-28
JP2001510824A (ja) 2001-08-07
EP1000027A1 (en) 2000-05-17
PT1000027E (pt) 2003-07-31
MY117734A (en) 2004-07-31
TR200000148T2 (tr) 2000-07-21
AR015133A1 (es) 2001-04-18
CN1125047C (zh) 2003-10-22
HUP0003198A3 (en) 2002-10-28
ZA986475B (en) 2000-01-21
DK1000027T3 (da) 2003-07-21
YU2200A (sh) 2002-03-18
CN1264366A (zh) 2000-08-23
SI1000027T1 (en) 2003-10-31
CA2296637C (en) 2005-11-15
UY25108A1 (es) 2000-12-29
ATE236123T1 (de) 2003-04-15
AU8631998A (en) 1999-02-16
HK1029339A1 (en) 2001-03-30
CZ296947B6 (cs) 2006-08-16
KR100336229B1 (ko) 2002-05-09
PL191602B1 (pl) 2006-06-30
RU2202542C2 (ru) 2003-04-20
PL338432A1 (en) 2000-11-06

Similar Documents

Publication Publication Date Title
ES2195366T3 (es) Modificacion termodinamicamente estable de 1-(4-carbazoliloxi)-4-(2-(2-metoxifenoxi)etillamino)-2-propanol, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
UY24555A1 (es) Nuevos compuestos
ES2112650T3 (es) Sales de un derivado de indol antimigraña.
CR20140368A (es) Derivados y composiciones de isoindol 4´-0-sustituidos, composiciones que las comprenden y metodos de uso de los mismos (divisional 11036)
DK1263730T3 (da) Aminderivater til behandling af apoptose
HN2002000300A (es) Nuevos derivados de piperazina
MX9202166A (es) Derivados de amidino fenil alanina, procedimiento para su preparacion su empleo y agentes que los con tienen en calidad de anticoagulantes.
HN2002000198A (es) Composiciones farmaceuticas de amlodipina y atorvastatina
ECSP003792A (es) Cristal de 4-carboxamino-1,2,3,4-tetrahidroquinolina 2-sustituida
UY27461A1 (es) Formas pseudopolimorficas de cardevilol.
MXPA04000443A (es) Metodo novedoso para la sintesis de derivados del acido (2s, 3as, 7as)-1-[(s)-alanil]-octahidro-1h-indol-2-carboxilico y la aplicacion en la sintesis de perindopril.
SV1999000115A (es) Derivados de sulfonamida ref. x-12301
HN2001000235A (es) Derivados puentes de piperazina
MX9204342A (es) Indoles.
ES2189072T3 (es) Nuevo benzo-cicloalquenos heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR014146A1 (es) Compuestos de triazina, su uso en terapia, composiciones farmaceuticas que los contienen, proceso para su manufactura e intermediarios de sintesis
DK0775113T3 (da) N-substituerede azabicycloheptan-derivater som neuroleptika osv.
ES2130548T3 (es) Nuevos derivados alquil-amino-indanos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
HN2001000119A (es) S-metil-dihidro -ziprasidona para el tratamiento de trastornos psiquiatricos y oculares.
AR015147A1 (es) Compuestos de 1-bis-trifluorometilbenzoil-2-indolilmetil-4-bencilamino-metil-piperazina, medicamentos que los contienen, y procedimiento para supreparacion
ES2128031T3 (es) Forma cristalina y polimorfica de (s,s,s)-n-(1-(2-carboxi-3-(n2-mesilisilamino)propil)-1-ciclopentilcarbonil)tirosina.
ECSP982599A (es) Modificacion termodinamicamente estable de 1-(4-carbazoliloxi)-3-[2-(2-metoxifenoxi) etilamino]-2-propanol, proceso para su preparacion y composicion farmaceutica que lo contiene
ES2132429T3 (es) Disacaridos de antraciclina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2147825T3 (es) Derivados tetraciclicos de la 1,4-oxazina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR046718A1 (es) Compuestos de benzazepina y composiciones farmaceuticas que los contienen.